Zobrazeno 1 - 10
of 16
pro vyhledávání: '"N Martinez Casanova"'
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f4e061860bee73d9b82a64e9a7e98c2
https://doi.org/10.1136/ejhpharm-2022-eahp.71
https://doi.org/10.1136/ejhpharm-2022-eahp.71
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance The overall survival of patients with multiple myeloma (MM) has changed dramatically in the last decade. Immunotherapy has emerged as a promising treatment, such as daratumumab. This human monoclonal IgG kappa antibody that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2d5d8e630a8856659ae44eb226917f8
https://doi.org/10.1136/ejhpharm-2021-eahpconf.283
https://doi.org/10.1136/ejhpharm-2021-eahpconf.283
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Tocilizumab is an anti-human IL-6 receptor monoclonal antibody used in the treatment of cytokine release syndrome in patients with pneumonia associated with coronavirus disease. Despite the data from the COVACTA study, tocil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::293d45dd7615d4e118d3e225b2989e7a
https://doi.org/10.1136/ejhpharm-2021-eahpconf.170
https://doi.org/10.1136/ejhpharm-2021-eahpconf.170
Autor:
M Sánchez-Argaiz, N Martinez-Casanova, E Sanchez-Yañez, I Moya-Carmona, F Gómez-Derueda, B Cancela-Díez
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance Immune checkpoint inhibitors (ICIs) represent a milestone therapy in many types of cancer, such as melanoma. Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody with antitumour activity in melanoma. Only a fe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6acd31ff5630921cb0ce5c585411230b
https://doi.org/10.1136/ejhpharm-2021-eahpconf.269
https://doi.org/10.1136/ejhpharm-2021-eahpconf.269
Autor:
F. Apolo Carvajal, I Cañamares Orbis, M. González Martínez, B Caliz Hernandez, H Hernandez Ovejero, MT Llanos Garcia, A. Escudero Brocal, A Aranguren Oyarzábal, I Mayorga Bajo, E Capilla Santamaría, N Martinez Casanova
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance The occupational risk due to exposure to hazardous drugs (HDs) has been a mounting concern to healthcare professionals, including in nursing homes. Aim and objectives To study the impact of a strategy to improve safe handlin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba73f2055311bd74beeba53360568a01
https://doi.org/10.1136/ejhpharm-2020-eahpconf.265
https://doi.org/10.1136/ejhpharm-2020-eahpconf.265
Publikováno v:
Eur J Hosp Pharm
Background Lapatinib has been approved for the treatment of patients with advanced stage HER2-positive breast cancer (BC) patients with moderate survival rates. Purpose To analyse the prescription profile used and the demographic and clinical charact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ae30ab598771999ca2e3e67b423fdb0
https://europepmc.org/articles/PMC7535278/
https://europepmc.org/articles/PMC7535278/
Autor:
M Carrasco Gomariz, N Martinez Casanova, M Lopez Martinez, A Cahue Urrutia, A Madrid Paredes, S Guijarro Herrera
Publikováno v:
Eur J Hosp Pharm
Background Proton pump inhibitors (PPIs) are often used inappropriately, without an indication, or for longer durations than recommended. Deprescribing is defined as the reduction, withdrawal or discontinuation of inappropriate medication. We aimed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c1c5c8ee29039af717e7f855f516479
https://doi.org/10.1136/ejhpharm-2018-eahpconf.97
https://doi.org/10.1136/ejhpharm-2018-eahpconf.97
Autor:
M Carrasco Gomariz, Rocío López-Sepúlveda, N Martinez Casanova, M Rodríguez Goicoechea, F Artime Rodríguez, I. Vallejo Rodríguez, J Cabeza Barrera, MA Calleja Hernández
Publikováno v:
European Journal of Hospital Pharmacy. 23:A3.2-A4
Background The switch from the intravenous (IV) formulation to the subcutaneous (SC) formulation of abatacept (ABA) had been analysed in clinical trials but there are few data regarding the effectiveness and safety of the SC formulation in clinical p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c199236cf00e40e8bb8884b9cb110ee
https://doi.org/10.1136/ejhpharm-2016-000875.7
https://doi.org/10.1136/ejhpharm-2016-000875.7
Autor:
J Cabeza Barrera, MA Calleja Hernández, CM Valencia Soto, Rocío López-Sepúlveda, F Artime Rodríguez, N Martinez Casanova, M Carraco Gomariz
Publikováno v:
European Journal of Hospital Pharmacy. 23:A5.2-A5
Background Viral hepatitis is a major public health problem, affecting millions of people worldwide. There is a great need for cost effectiveness analysis in real life settings as newly introduced treatment strategies result in high sustained viral r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e95c3f3326d61c3e166ed8c1b8d3200
https://doi.org/10.1136/ejhpharm-2016-000875.11
https://doi.org/10.1136/ejhpharm-2016-000875.11
Autor:
Miguel Ángel Calleja-Hernández, M Carrasco-Gomariz, C Valencia-Soto, F Artime-Rodriguez-Hermida, M Ferrit-Martin, N Martinez-Casanova
Publikováno v:
European Journal of Hospital Pharmacy. 23:A86.1-A86
Background Biological agents are used to treat rheumatic diseases. Patients are initially treated at the recommended dose according to the results of clinical trials but there is no current consensus on what attitude to take following remission. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd393ccc60136d3d4fcf05ac051eaecc
https://doi.org/10.1136/ejhpharm-2016-000875.194
https://doi.org/10.1136/ejhpharm-2016-000875.194